Pfizer Inc. is intensifying its focus on obesity treatments through a significant acquisition valued at nearly $5 billion. The pharmaceutical giant announced its intention to acquire Metsera Inc., a development-stage company specializing in obesity therapies, for $47.50 in cash per share. This offer represents a notable premium of over 42% from Metsera’s most recent closing price.
The acquisition could also include an additional payment of $22.50 per share, contingent upon the advancement of Metsera’s product pipeline. Currently, Metsera does not have any drugs on the market but boasts a promising pipeline with four programs in clinical development and one in mid-stage testing. This strategic move aims to enhance Pfizer’s capabilities in both oral and injectable treatments for obesity.
Pfizer’s CEO, Albert Bourla, emphasized the growing concern surrounding obesity, linking it to over 200 associated health conditions. He characterized this as “a large and growing space” for the company to explore. The rising demand for effective obesity treatments has been largely driven by the success of leading products such as Wegovy from Novo Nordisk and Zepbound from Eli Lilly and Co. These drugs have shown remarkable weight loss results and have generated substantial revenues, with Eli Lilly’s Zepbound reporting $5.7 billion in sales in just the first half of this year.
Despite not having any obesity treatments available currently, Pfizer has been making strides in clinical development. Earlier this year, the company made the decision to halt its own once-daily pill treatment before it could enter late-stage testing, which is often the most costly phase of drug development.
The boards of both Pfizer and Metsera have approved the deal, which is still pending approval from Metsera’s shareholders. Additionally, the acquisition is expected to close in the fourth quarter of this year, subject to regulatory approvals.
Following the announcement, Pfizer’s shares saw a slight increase, rising 38 cents to $24.40 before the market opened, while Metsera’s stock surged nearly 61%. As the obesity treatment market continues to expand dramatically, the acquisition positions Pfizer to better compete and potentially lower costs for patients seeking effective therapies.
